Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.43 USD | +3.19% | +5.24% | -5.35% |
May. 07 | Transcript : Viemed Healthcare, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 06 | Earnings Flash (VMD) VIEMED HEALTHCARE Reports Q1 Revenue $50.6M | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 235.3 | 303.8 | 206.8 | 287.4 | 302.1 | 287.7 | - |
Enterprise Value (EV) 1 | 235.3 | 303.8 | 206.8 | 287.4 | 302.1 | 287.7 | 287.7 |
P/E ratio | 29.5 x | 9.95 x | 23.7 x | 47.3 x | 31.4 x | 22.8 x | 17.2 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | 2.93 x | 2.31 x | 1.77 x | 2.07 x | 1.65 x | 1.32 x | 1.18 x |
EV / Revenue | 2.93 x | 2.31 x | 1.77 x | 2.07 x | 1.65 x | 1.32 x | 1.18 x |
EV / EBITDA | 12.4 x | 7.35 x | 7.06 x | 9.58 x | 7.02 x | 5.52 x | 4.87 x |
EV / FCF | - | - | - | - | 15.8 x | 16.2 x | 14.6 x |
FCF Yield | - | - | - | - | 6.33% | 6.19% | 6.85% |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 37,953 | 39,145 | 39,608 | 38,020 | 38,489 | 38,821 | - |
Reference price 2 | 6.200 | 7.760 | 5.220 | 7.560 | 7.850 | 7.410 | 7.410 |
Announcement Date | 3/3/20 | 3/3/21 | 3/7/22 | 3/2/23 | 3/6/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net sales 1 | 80.26 | 131.3 | 117.1 | 138.8 | 183 | 217.4 | 243.5 |
EBITDA 1 | 19.03 | 41.33 | 29.28 | 30.02 | 43.06 | 52.1 | 59.1 |
EBIT 1 | 9.11 | 26.78 | 11.58 | 8.252 | 14.33 | 16.5 | 18.9 |
Operating Margin | 11.35% | 20.4% | 9.89% | 5.94% | 7.83% | 7.59% | 7.76% |
Earnings before Tax (EBT) 1 | 8.796 | 26.36 | 12.5 | 8.99 | 14.39 | 16.2 | 18.6 |
Net income 1 | 8.525 | 31.53 | 9.126 | 6.222 | 10.24 | 11.7 | 17.7 |
Net margin | 10.62% | 24.01% | 7.8% | 4.48% | 5.6% | 5.38% | 7.27% |
EPS 2 | 0.2100 | 0.7800 | 0.2200 | 0.1600 | 0.2500 | 0.3250 | 0.4300 |
Free Cash Flow 1 | - | - | - | - | 19.12 | 17.8 | 19.7 |
FCF margin | - | - | - | - | 10.45% | 8.19% | 8.09% |
FCF Conversion (EBITDA) | - | - | - | - | 44.4% | 34.17% | 33.33% |
FCF Conversion (Net income) | - | - | - | - | 186.65% | 152.14% | 111.3% |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/3/20 | 3/3/21 | 3/7/22 | 3/2/23 | 3/6/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 31.96 | 32.26 | 33.31 | 35.76 | 37.51 | 39.56 | 43.31 | 49.4 | 50.74 | 50.59 | 53.8 | 55.6 | 58 |
EBITDA 1 | 9.549 | 7.273 | 6.458 | 6.982 | 9.306 | 8.328 | 9.81 | 12.08 | 12.84 | 10.1 | 11.8 | 13 | 14.1 |
EBIT 1 | 4.665 | 2.248 | 1.001 | 1.469 | 3.534 | 1.934 | 2.995 | 4.383 | 5.289 | 2.204 | 3.8 | 4.8 | 5.7 |
Operating Margin | 14.6% | 6.97% | 3.01% | 4.11% | 9.42% | 4.89% | 6.92% | 8.87% | 10.42% | 4.36% | 7.06% | 8.63% | 9.83% |
Earnings before Tax (EBT) 1 | 5.055 | 2.507 | 1.388 | 1.511 | 3.584 | 2.018 | 3.058 | 4.239 | 5.076 | 2.121 | 3.8 | 4.7 | 5.6 |
Net income 1 | 4.087 | 1.762 | 0.967 | 1.055 | 2.438 | 1.517 | 2.33 | 2.919 | 3.477 | 1.603 | 2.7 | 3.4 | 4 |
Net margin | 12.79% | 5.46% | 2.9% | 2.95% | 6.5% | 3.84% | 5.38% | 5.91% | 6.85% | 3.17% | 5.02% | 6.12% | 6.9% |
EPS 2 | 0.1000 | 0.0400 | 0.0200 | 0.0300 | 0.0600 | 0.0400 | 0.0600 | 0.0700 | 0.0800 | 0.0400 | 0.0700 | 0.0800 | 0.1000 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/7/22 | 5/3/22 | 8/2/22 | 11/1/22 | 3/2/23 | 5/8/23 | 8/9/23 | 11/1/23 | 3/6/24 | 5/6/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | - | 19.1 | 17.8 | 19.7 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | 13 | - | - | - | - | - |
Capex / Sales | - | 9.93% | - | - | - | - | - |
Announcement Date | 3/3/20 | 3/3/21 | 3/7/22 | 3/2/23 | 3/6/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.35% | 288M | |
+25.52% | 88.99B | |
-24.52% | 74.82B | |
-5.56% | 25.03B | |
+4.31% | 17.88B | |
-14.25% | 16.43B | |
+2.97% | 15.77B | |
+70.11% | 13.09B | |
+79.20% | 13.21B | |
+40.44% | 12.9B |
- Stock Market
- Equities
- VMD Stock
- Financials Viemed Healthcare, Inc.